Oryzon Genomics announced that it will present preliminary top-line clinical results from the first-in-man clinical trial to assess safety, tolerability and pharmacokinetics of ORY-2001, a novel epigenetic drug for treatment of neurodegenerative diseases, at the 13th ADPD International Conference to be held in Vienna, Austria from March 29, 2017 to April 2, 2017. Preliminary data on safety, pharmacokinetics, target engagement and surrogate biomarker in peripheral samples in the SAD and MAD phases in 88 healthy volunteers administered with different doses of ORY-2001 will be presented by Dr. César Molinero, Medical and Clinical Operations Director of the company on March 31st on the symposium 38 - short oral session 03 - short oral presentations of selected posters - that starts at 17.15 PM CET. ORY-2001 is a highly selective dual LSD1-MAOB inhibitor. The molecule, which focuses on cognitive decline and memory loss, has a good safety profile and therapeutic index in preclinical trials. In nontransgenic AD mouse models, long-term treatments with the drug demonstrated a marked cognitive improvement. The company has also recently presented data that supports the potential application of this experimental drug in other CNS neuroinflammatory disorders such as Multiple Sclerosis. LSD1 is an epigenetic modulator, which regulates histone methylation. Epigenetic approaches to modify the progression of various neurodegenerative diseases focus on producing changes in patterns of gene expression in neurons and also in glia cells and are of interest for the pharmaceutical industry. Oryzon has a highly competitive and productive Epigenetics Platform, centered around the development of LSD1 inhibitors, with a first forerunner program licensed to Roche (ORY-1001/RG6016) that has recently finished Phase I/IIA in acute leukemia and is currently being explored in an ongoing Phase I clinical trial in Small Cell Lung Cancer that validates the platform scientifically and clinically. This Platform has so far produced two additional programs: ORY-2001, already in clinical development with multiple indication opportunities that is pioneering the histone demethylases field in neurodegenerative disorders; and ORY-3001, also against LSD1, currently in preclinical development for a yet undisclosed non-oncological orphan indication.